

**FOR IMMEDIATE RELEASE:**

**EBI ANNOUNCES COMPLETION OF EA-230 PHASE IA SINGLE DOSE  
HUMAN SAFETY TRIALS**

**Washington DC, August 30, 2005** – Privately held Exponential Biotherapies, Inc. (“EBI”), a Washington DC based drug discovery and development company, today announced that it has completed a Phase Ia safety trial on its lead drug candidate, a small immunomodulatory peptide designated EA-230. The trial was designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of EA-230 in healthy volunteers. The target application for EA-230 is a group of disorders commonly known as systemic inflammatory response syndrome (or “SIRS”), which includes the clinical condition commonly known as sepsis.

This study was a double blind, randomized, single-dose, placebo-controlled, dose escalation study with 4 groups of 8 subjects and was conducted by SGS Life Science Services, in Wavre, Belgium.

“We are pleased with the outcome of this study, because it demonstrated that EA-230 was well-tolerated, without any significant treatment-emergent adverse events”, said Zsolt Harsanyi, Ph.D., EBI’s Chairman and CEO. “The results of this Phase Ia study will enable EBI to proceed to a Phase Ib study, in which we will assess the effect of EA-230 following the introduction of a bacterial endotoxin in healthy volunteers. We expect to initiate the Phase Ib trial within weeks.”

EBI is a privately held, Washington DC based drug discovery and development company with a growing pipeline of novel small molecule drugs designed to treat a wide range of severe inflammatory disorders such as septic shock, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents.

**Forward-looking statements**

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials (including our ability to initiate and complete subsequent clinical trials involving EA-230 or any other product candidate); risks that subsequent clinical trials may show EA-230 is not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of EA-230 or any of our other product candidates; manufacturing issues relating to EA-230 or any other drug candidate; our ability to obtain financial resources necessary to

support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

#### Contact

Zsolt Harsanyi, Ph.D., Chairman and CEO 703-883-3701

